On August 30, 2024 Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, reported its executive management will participate in the H.C. Wainwright 26th Annual Global Investment Conference in a Fireside Chat presentation (virtual) and one-on-one meetings (Press release, Purple Biotech, AUG 30, 2024, View Source;id=318527&p=2338652&I=1206939-c7Z3G6f3m8 [SID1234646238]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference is being held on September 9-11, 2024, and the virtual Fireside Chat will be available on-demand starting on Monday, September 9 at 7:00 AM ET on the Investor section of Purple Biotech’s website at www.purple-biotech.com for 30 days. Institutional investors interested in listening to Purple Biotech’s Fireside Chat may click on the following link (www.hcwevents.com/annualconference) to register for the conference.

Purple Biotech’s CEO, Gil Efron, will also conduct in-person one-on-one meetings with institutional investors at the conference’s in-person venue at the Lotte New York Palace Hotel in New York City.